Most discussion of graphene safety concerns toxicology — what the material does in a lung or a cell. Regulation is a different question, with a different answer. A material can be well characterized toxicologically and still be unlawful to place on a market, or lawful to sell and unlawful to use in a particular product.
This article covers the compliance dimension. It is a general orientation, not legal advice, and anyone placing graphene-containing products on a regulated market should engage a regulatory professional in the relevant jurisdiction.
Why Graphene Is Regulatorily Awkward
Chemical regulation is built around substance identity. A regulator asks: what substance is this, at what CAS number, with what composition?
Graphene resists that framing. Graphene, graphene oxide, reduced graphene oxide, and graphene nanoplatelets are chemically all carbon, but they behave very differently. Two products with identical elemental composition can have entirely different particle size, surface chemistry, and biological behaviour. Regulatory systems designed for molecules struggle with materials whose hazard profile is dominated by morphology.
The response across jurisdictions has been to layer nanomaterial-specific requirements on top of existing chemical frameworks, rather than to create separate regimes. This is why the compliance picture is fragmented.
The European Union: REACH
Under REACH, substances manufactured in or imported into the EU above one tonne per year per legal entity must be registered with ECHA. Graphene materials fall within scope as substances.
The significant development for nanomaterials came with amendments to the REACH annexes that introduced specific information requirements for nanoforms, applicable from the start of 2020. Registrants must characterize each nanoform or set of nanoforms they place on the market, providing particle size distribution, shape, surface chemistry, specific surface area, and other descriptors, and must address how those nanoforms are covered by the registration’s hazard and exposure assessment.
The practical consequences for a buyer:
- A registration covers specific nanoforms, not “graphene” generically. A supplier registered for one grade is not automatically covered for a materially different grade.
- Importers carry obligations. If you buy graphene from outside the EU and bring it in yourself, the registration duty may be yours, not your supplier’s. Buying through an EU-based supplier or an Only Representative changes who holds it.
- Safety data sheets must reflect the nanoform. An SDS that describes bulk graphite properties for a nanoplatelet product is a red flag.
- Downstream use must fall within the registered exposure scenarios. Using a material in an application the registrant did not cover creates an obligation on the downstream user.
Separate frameworks apply for specific end uses. Food contact materials, cosmetics, biocides, and medical devices each have their own authorization pathways, and in several of these a nanomaterial requires explicit approval rather than merely a compliant chemical registration. This is a significant barrier for graphene in packaging, discussed further in our article on graphene barrier films.
The United States: TSCA
In the US, industrial chemicals fall under TSCA, administered by the EPA. A substance not on the TSCA Inventory requires a Premanufacture Notice before commercial manufacture or import, giving EPA an opportunity to review and, if it chooses, impose conditions.
EPA has treated carbon nanomaterials as warranting case-by-case review, and has historically issued Significant New Use Rules for a number of them. A SNUR does not prohibit use, but it requires notification before a use outside the specified conditions, which effectively means checking whether your intended application falls inside the envelope of what was already reviewed.
Occupational exposure is regulated separately. NIOSH has published recommended exposure limits for carbon nanotubes and nanofibres; graphene-specific limits are less settled, and employers generally default to conservative handling practices for respirable nanoscale powders. Because graphene powders can have very low bulk density and high dustiness, this is a real operational concern rather than a paper exercise.
Asia
China operates a new chemical substance notification regime administered under MEE, with tiered requirements based on annual volume. Given the scale of Chinese graphene production, most material entering global supply chains has passed through this system, but importers into other jurisdictions cannot rely on it for their own compliance.
South Korea operates K-REACH, broadly modelled on the EU system with its own registration thresholds and timelines.
Japan regulates under the Chemical Substances Control Law, with its own inventory and notification process.
Taiwan, India, and several Southeast Asian jurisdictions have introduced or are introducing chemical inventory systems with nanomaterial provisions at varying stages of development.
The practical implication is that a global product requires jurisdiction-by-jurisdiction verification. A supplier’s claim of “full regulatory compliance” without specifying which jurisdictions and which nanoforms is not a claim you can rely on.
Labelling and Consumer-Facing Obligations
Several jurisdictions require nanomaterial ingredients to be declared on consumer products, most prominently in cosmetics in the EU. Some member states have operated national nanomaterial registers with their own reporting duties. If your product reaches consumers and contains graphene, the labelling question needs to be answered early, because it interacts with marketing decisions.
A Buyer’s Verification Checklist
- Ask for the registration number and the nanoform characterization it covers — not just confirmation that the supplier “is REACH registered.”
- Confirm who is the importer of record for material crossing into your jurisdiction.
- Check that your application falls within the registered uses and exposure scenarios.
- Review the SDS against the actual product. Bulk graphite hazard data on a nanoplatelet SDS indicates the supplier has not done the work.
- Identify sector-specific approvals required for your end market — food contact, medical device, cosmetics, biocidal — well before product design freezes.
- Document your own occupational controls. Regulatory inspection of nanomaterial handling focuses on ventilation, containment, and respiratory protection.
Regulation is not the reason graphene has been slow to commercialize; dispersion and cost are. But it is a reason that individual products fail late in development, when the discovery that a food-contact approval does not exist arrives after tooling has been ordered. Establishing the regulatory pathway at concept stage costs very little. Discovering it at launch costs a great deal.
This article is part of our Standards & Safety series. For the toxicological picture, see Graphene Safety: What We Know (and Don’t Know) About Health Risks. For environmental release and end-of-life, see our article on the environmental fate of graphene.
